biostudies-literatureUnknown6(1)Visco CLymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease 2019 (COVID-19) during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma patients. Here, we investigated the clinical behavior and clinical parameters of a large multicenter cohort of adult patients with different lymphoma subtypes, with the aim of identifying predictors of death. The study included 856 patients, of whom 619 were enrolled prospectively in a 1-year frame and were followed-up for a median of 66 days (range 1-395). Patients were managed as outpatient (not-admitted cohort, n = 388) or required hospitalization (n = 468), and median age was 63 years (range 1Blood advances327-338https://www.ebi.ac.uk/biostudies/studies/S-EPMC8516438biostudies-literatureA prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study.PMC8516438Mina RVisco CTosi PVallisa DMassaia MGuidetti AMarchesi FMerli FCoviello ETisi MCCairoli RPenna DLanza FVenditti ABruna RRomano ALa Barbera EOArcaini LPinto AGalimberti SRigacci LFerreri AJMScattolin ARamadan SCattaneo CCuneo ALadetto MCorso ACavo MTrentin LCilloni DDella Porta MCandoni ACorradini PMarchetti MITA-HEMA-COV investigatorsConconi APilerci SCardinali VVisani GBusca ASalvini MMarcheselli LMusto PTafuri ABocchia MBertu LGherlinzoni FTurrini MBonuomo VPetrucci LPassamonti FSelleri CFracchiolla NSassone MArmiento DKrampera MGambacorti-Passerini CfalseA prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study.Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease 2019 (COVID-19) during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma patients. Here, we investigated the clinical behavior and clinical parameters of a large multicenter cohort of adult patients with different lymphoma subtypes, with the aim of identifying predictors of death. The study included 856 patients, of whom 619 were enrolled prospectively in a 1-year frame and were followed-up for a median of 66 days (range 1-395). Patients were managed as outpatient (not-admitted cohort, n = 388) or required hospitalization (n = 468), and median age was 63 years (range 12022-01-01T00:00:00Z2022 Jan2026-05-09T01:25:21.853Z2022-02-11T15:14:02.113ZS-EPMC85164383464438510.1182/bloodadvances.2021005691